Mucosal IgA fused nanobody as a non-invasive, cost-effective prophylaxis and therapeutic option against major SARS-CoV-2 variants

Specialist researcher holding microscope slide analyzing blood sample working at coronavirus vaccine development during virus examination in microbiology hospital laboratory. Biochemistry experiment

Researchers from the United States developed an affordable, non-invasive, inhalable prophylactic treatment consisting of immunoglobulin (Ig) A fused nanobodies against the SARS-CoV-2 Omicron variant.

Samsung’s Cyber Week deals are still live

Previous article

Exploring neurodevelopment among Zika virus-exposed children without Zika syndrome

Next article

You may also like


Leave a reply

Your email address will not be published. Required fields are marked *

More in News